On 4 September 2026, LONGSYS (09976.HK) announced that the offer price has been fixed at HKD 236.00 per share, with the allotment results expected to be announced on 7 September and trading to commence on the Main Board at 9:00 a.m. on 8 September, in board lots of 50 shares.
On 4 September 2026, the public offering of EXCELLAND ROBOTICS (03231.HK) closed, with margin financing of HKD 4.214 billion and an actual oversubscription of 95.79 times; the global offering comprised 45,000,000 shares (public offering 5% / international placing 95%), with the enlarged total share capital at 416 million shares, the offering representing approximately 10.81%, and an offer price range of HKD 14.450-19.550 per share.
On 4 September 2026, MEDCAPTAIN (02041.HK) opened 18.5% lower at HKD 12.59 in grey-market trading, with the main board listing scheduled for 7 September; the Company is a global medical device provider across life support, minimally invasive intervention and in-vitro diagnostics, ranking first in China's infusion workstation market from 2018 to 2025; its products are distributed to over 140 countries and 6,000+ hospitals globally.
On 3 September 2026, SALUBRIS filed its listing application with HKEX, with Goldman Sachs, Citigroup and CITIC Securities as joint sponsors; according to Frost & Sullivan, the Company ranked second in China by 2025 in-hospital sales of cardiovascular drugs (with an 11.3% market share) and second among domestic enterprises by the number of CKM syndrome pipeline candidates; in 2025, CKM syndrome drug revenue reached RMB 2,899.1 million, with innovative drugs accounting for 52.1% of revenue.
On 3 September 2026, LONGSYS (09976.HK) closed its public offering, with total margin financing of HKD 17.047 billion, a public offering size of HKD 627 million and an actual margin financing multiple of 27.16 times as of 12:00 noon; the maximum offer price is HKD 240.60, with each board lot of 50 shares implying an application fee of approximately HKD 12,151.32, pricing scheduled for 7 September and listing expected on 8 September.
On 3 September 2026, E.VAT MASTER filed its listing application with HKEX, with CICC and Shenwan Hongyuan Securities (H.K.) acting as joint sponsors; according to CIC, the Company was the largest cross-border e-commerce compliance service provider globally and in China by 2025 sales (with a 21.5% market share in China), recording 2025 revenue of RMB 528.5 million, up 50.8% year on year, and having served over 264,000 paying users cumulatively.
On 3 September 2026, ANJI MICRO (688019.SH) announced that it had filed its H-share issuance and listing application with HKEX in confidential form on 2 September 2026, and will complete the CSRC filing procedures as required; the issuance and listing remains subject to approvals from the CSRC, the Hong Kong Securities and Futures Commission and HKEX, and there remains uncertainty.
Medcaptain (02041.HK) closed its public offering at 12:00 noon today (2 September). As of 11:50 a.m., total margin financing amounted to approximately HKD 19.4 billion, representing an oversubscription of approximately 323.32 times against the public offering size of HKD 60 million. The offer price is set at HKD 15.42 per share, with each board lot comprising 100 shares and an application fee of approximately HKD 1,557.55, and listing is expected on 7 September. Net proceeds are approximately HKD 496 million, of which 35% will be used for R&D investment.
NewTimeSpace News: In August 2026, the Hong Kong primary market continued the cooling trend seen since July, with only two new listings completing their IPOs during the month — NASN TECH (02261.HK), listed on 7 August, and Ingenic Semiconductor Co., Ltd. (03223.HK), listed on 25 August. Despite the small number, the two new listings presented starkly different pictures in subscription and debut performance.
NewTimeSpace News: On 1 September 2026, AMLOGIC (688099.SH) announced that its application for H-share issuance and listing on the Hong Kong Stock Exchange has obtained CSRC filing approval, with no more than 53,815,500 overseas listed ordinary shares to be issued; the issuance and listing remains subject to approvals from the Hong Kong Securities and Futures Commission, the Hong Kong Stock Exchange and market conditions, and there remains uncertainty.
NewTimeSpace News: On 31 August 2026, Jiangxi Tongbo Technology Co., Ltd. filed its listing application with HKEX, with Sinolink Securities (Hong Kong) as the sole sponsor; according to Frost & Sullivan, the Company was the world's 10th largest electrolytic copper foil producer by 2025 sales volume with a market share of approximately 2.3%, and is strategically focusing on RTF and HVLP electronic circuit copper foil for the AI and high-performance computing industry.
NewTimeSpace News: On 31 August 2026, Zhejiang IPLUSMOBOT Technology Co., Ltd. filed its listing application with HKEX, with CICC as the sole sponsor; according to CIC, by 2025 revenue the Company ranked among the global top 10 intelligent mobile robot companies, and among the global top 5 domestic companies in the industrial intelligent mobile robot segment.
NewTimeSpace News: On 31 August 2026, Anew Health Limited filed its listing application with HKEX, with VBG Capital Limited as the sole sponsor; the Company provides non-surgical, non-invasive and non-pharmaceutical pain management services in Hong Kong under the "Functional Regeneration" brand, operating three service centres in Causeway Bay, Tsim Sha Tsui and Sha Tin, each of approximately 18,000 square feet.
NewTimeSpace News: On 31 August 2026, Ningbo Sunny Smart Autotech Company Limited filed its listing application with HKEX, with CICC and CITIC Securities as joint sponsors; according to Frost & Sullivan, the Company ranked first globally in automotive camera products by 2025 shipment volume, with a market share equivalent to the combined share of the two next-ranked competitors, and its automotive lens groups have ranked first globally in market share for 14 consecutive years.
NewTimeSpace News: On 31 August 2026, ProteLight Pharmaceuticals (Jiangsu) Co., Ltd. filed its listing application with HKEX, with CITIC Securities as the sole sponsor; its core product PL-5 is the world's first NDA-approved first-in-class gana-based drug, having received NMPA approval in June 2026 for the treatment of secondary infections of burn wounds, with plans to expand into indications including diabetic foot infections.
Newtimespace News: Guangxi Yuchai Marine and Genset Power Co., Ltd. refiled its listing application with the Hong Kong Stock Exchange on 31 August, with China Merchants Securities (International) and China Galaxy International acting as joint sponsors. According to Frost & Sullivan, the company ranked first in China by sales revenue of power‑generation engines in 2025, and second for medium‑ and high‑speed marine engines over the same period. Its overseas sales surged 120.5% year‑on‑year in the first half of 2026.
